CM
ONCS

Crestline Management’s OncoSec Medical Incorporated ONCS Stock Holding History

Crestline Management’s Portfolio ONCS Stock Details ONCS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-918
Closed -$379K – 315
2018
Q1 		$379K Buy
+918
New +$377K 0.05% 201

Other funds holding ONCS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Crestline Management's ONCS Position: Q2 2018 in Review

Crestline Management sold out of OncoSec Medical Incorporated (ONCS) in Q2 2018, closing a stake of 918 shares — an estimated $379K sold.

Crestline Management first reported a position in ONCS in Q1 2018 and held it in 1 quarter. The position peaked at $379K in Q1 2018. 34 funds tracked by Wall St. Rank hold ONCS as of Q2 2018.

  • Crestline Management reported no remaining OncoSec Medical Incorporated position as of Q2 2018 after selling out during the quarter.
  • Crestline Management sold 918 OncoSec Medical Incorporated shares in Q2 2018, an estimated $379K.
  • Crestline Management first reported a position in OncoSec Medical Incorporated in Q1 2018 and held it in 1 quarter.
  • Crestline Management's OncoSec Medical Incorporated position peaked at $379K in Q1 2018.
  • 34 funds tracked by Wall St. Rank held OncoSec Medical Incorporated as of Q2 2018.

Based on Crestline Management's 13F filing for Q2 2018, filed 14 Aug 2018.